Prospective Grant of Exclusive License: Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods

Özet

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Application Serial Number 08/231,565, entitled ``Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods'' and related foreign patent applications to Therion Biologics Corporation, of Cambridge, Massachusetts. The patent rights in this invention have been assigned to the United States of America. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This license will be limited to the field of treatment and/or prevention of cancer in humans using recombinant poxviruses comprising melanoma antigens. The melanoma antigens may be limited to MART-1 and gp100, encoded by Sequence ID Nos. 1 and 26 (described in patent application 08/231,565), respectively, and fragments thereof. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidenc